A Long COVID Definition

A Chronic, Systemic Disease State with Profound Consequences

Millions of individuals worldwide are experiencing a diversity of symptoms and health impacts after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These long-term health effects are known as Long COVID. Long COVID has serious medical, social, and economic consequences worldwide and can profoundly impact patients’ health, functioning, quality of life, and work capacity.

At the request of the Administration for Strategic Preparedness and Response and the Office of the Assistant Secretary for Health (OASH), a committee convened by the National Academies of Sciences, Engineering, and Medicine developed a consensus definition for Long COVID that can be applied for broad uses. The committee comprised technical experts across disciplines and members whose lived experience as patients could inform the process of developing a definition.

Disease definition is an essential tool in health care that aids diagnosis, treatment, and research; it also has implications for access to supportive services post diagnosis. Government bodies, health organizations, and researchers have published working definitions and descriptions of Long COVID, but there is not yet a common, agreed-upon definition for Long COVID. Inconsistencies in definitions have created challenges, and a consensus definition could promote consistency in diagnosis, aid awareness efforts, help patients access appropriate care, services, and benefits, and help harmonize Long COVID research and surveillance. This report, A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences, presents the 2024 NASEM Long COVID Definition, summarizes the evidence
infection but does not require laboratory evidence of a previous infection. Symptoms or conditions must be present for a duration of at least 3 months, but the timing of those 3 months is unspecified. It is not necessary for symptoms to be present continuously from the time of the acute infection.

More than 200 symptoms and diagnosable conditions have been reported to occur with Long COVID, some patients have a fluctuating time course or delayed onset of symptoms, and no definitive Long COVID biomarker has yet been discovered. The definition provides a list of possible Long COVID symptoms and conditions, but many other manifestations are possible. Symptoms can range from mild to severe and can cause functional impairment. Long COVID may be diagnosed alongside associated conditions.

**BOX 1
2024 NASEM Long COVID Definition**

Long COVID (LC) is an infection–associated chronic condition (IACC) that occurs after SARS–CoV–2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems.

**LC manifests in multiple ways.** A complete enumeration of possible signs, symptoms, and diagnosable conditions of LC would have hundreds of entries. Any organ system can be involved, and LC patients can present with

- **single or multiple symptoms, such as:** shortness of breath, cough, persistent fatigue, post-exertional malaise, difficulty concentrating, memory changes, recurring headache, lightheadedness, fast heart rate, sleep disturbance, problems with taste or smell, bloating, constipation, and diarrhea.

- **single or multiple diagnosable conditions, such as:** interstitial lung disease and hypoxemia, cardiovascular disease and arrhythmias, cognitive impairment, mood disorders, anxiety, migraine, stroke, blood clots, chronic kidney disease, postural orthostatic tachycardia syndrome (POTS) and other forms of dysautonomia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), fibromyalgia, connective tissue diseases, hyperlipidemia, diabetes, and autoimmune disorders such as lupus, rheumatoid arthritis, and Sjogren’s syndrome.

*continued*
Important Features of LC:

- LC can follow asymptomatic, mild, or severe SARS-CoV-2 infection. Previous infections may have been recognized or unrecognized.

- LC can be continuous from the time of acute SARS-CoV-2 infection or can be delayed in onset for weeks or months following what had appeared to be full recovery from acute infection.

- LC can affect children and adults, regardless of health, disability, or socioeconomic status, age, sex, gender, sexual orientation, race, ethnicity, or geographic location.

- LC can exacerbate pre-existing health conditions or present as new conditions.

- LC can range from mild to severe. It can resolve over a period of months or can persist for months or years.

- LC can be diagnosed on clinical grounds. No biomarker currently available demonstrates conclusively the presence of LC.

- LC can impair individuals’ ability to work, attend school, take care of family, and care for themselves. It can have a profound emotional and physical impact on patients and their families and caregivers.

**FIGURE 1** 2024 NASEM Long COVID Definition.

**The Disease State of Long COVID**

**An Infection-Associated Chronic Condition (IACC)**

**Common Symptoms**
- Can be mild to severe

**Diagnosable Conditions**
- New or worsening of preexisting conditions

**Important Features**
- Long COVID can affect children and adults, regardless of health, disability, socioeconomic status, age, sex, gender, sexual orientation, race, ethnicity, or geographic location
- Long COVID can resolve over a period of months or can persist for months or years
- Long COVID can be diagnosed on clinical grounds. No biomarker currently available demonstrates conclusively the presence of Long COVID
- Long COVID can impair affected individual’s ability to work, attend school and care for themselves and have a profound emotional and physical impact on patients, families, and caregivers

**PATHOBIOLOGY OF LONG COVID**

- Cardiovascular disease
- Arhythmias
- Blood clots
- Cognitive impairment
- Migraine
- Stroke
- Mood disorders
- Chronic kidney disease
- Postural orthostatic tachycardia syndrome (POTS) and other forms of dysautonomia
- Mast Cell Activation Syndrome (MCAS)
- Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- Lupus, Sjogren’s, Fibromyalgia, and other connective tissue or autoimmune disorders
- Interstitial lung disease
- Hypoxemia
- Postural orthostatic tachycardia syndrome (POTS) and other forms of dysautonomia
- Mast Cell Activation Syndrome (MCAS)
- Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
- Lupus, Sjogren’s, Fibromyalgia, and other connective tissue or autoimmune disorders
- Interstitial lung disease
- Hypoxemia
- Common Symptoms
- Persistent Fatigue
- Difficulty Concentrating
- Memory Changes
- Recurring Headaches
- Lightheadedness/Fat Heart Rate
- Sleep Disturbance
- Shortness of Breath/Cough
- Prolems with Taste
- Problems with Smell
- Bloating/Constitution/Diarrhea

Many other symptoms have been observed.

**Diagnosable Conditions**
- New or worsening of preexisting conditions

**Important Features**
- Long COVID can affect children and adults, regardless of health, disability, socioeconomic status, age, sex, gender, sexual orientation, race, ethnicity, or geographic location
- Long COVID can resolve over a period of months or can persist for months or years
- Long COVID can be diagnosed on clinical grounds. No biomarker currently available demonstrates conclusively the presence of Long COVID
- Long COVID can impair affected individual’s ability to work, attend school and care for themselves and have a profound emotional and physical impact on patients, families, and caregivers

**FIGURE 1** 2024 NASEM Long COVID Definition.
Long COVID can affect anyone, regardless of the patient’s identity, demographics, or previous state of health. Various risk factors, such as underlying comorbid conditions, may influence the risk and presentation of COVID-19 and Long COVID in a particular individual, but risk factors are not included explicitly in the definition.

**ADOPTION AND IMPLEMENTATION**
Federal, state, tribal, local, and territorial health authorities; clinical societies and associations; public health practitioners; clinicians; payers; researchers; drug industry; employers; educators; international organizations; and patients should adopt the 2024 NASEM Long COVID Definition and should use the term Long COVID. The definition is intended to be applied to many purposes (clinical, research, and public health surveillance), but the committee notes that there is flexibility within the broad definition; for example, to restrict research eligibility to a subset of Long COVID patients.

**MONITORING AND UPDATES**
The 2024 NASEM Long COVID Definition will need to be paired with a dissemination and education campaign to inform the public and key stakeholders. It will be valuable to have mechanisms in place for gauging how the 2024 NASEM Long COVID Definition is understood, how it is being used, what other elements need to be added, and whether it is being applied in a consistent and standardized way. The OASH Office of Long COVID Research and Practice and the Long COVID Coordination Council should lead the coordination and collaboration efforts across federal, state, tribal, local, and territorial agencies and other relevant entities, including international organizations.

The 2024 NASEM Long COVID Definition will evolve as new evidence emerges and the understanding of Long COVID matures. A research agenda to improve the definition could focus on the key elements articulated above. In no more than 3 years, or when triggered by the emergence of relevant new knowledge, the OASH Office of Long COVID Research and Practice should convene a multi-disciplinary group, including individuals with lived experience, to reexamine and update the definition.

**CONCLUDING REMARKS**
The 2024 NASEM Long COVID Definition recognizes the heterogeneity and complexity of Long COVID presentations and how Long COVID can affect individuals in multiple and profound ways. It is imperative to foster greater awareness, understanding, and support for those with Long COVID.
COMMITTEE ON EXAMINING THE WORKING DEFINITION FOR LONG COVID

Harvey V. Fineberg (Chair), Gordon and Betty Moore Foundation; Kevin M. Alexander, Stanford University; Donald Berwick, Institute for Healthcare Improvement; Karyn Bishof, Long COVID Patient Advocate and COVID-19 Longhauler Advocacy Project (Ci9LAP); Lily Chu, International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis; Betty Diamond, Feinstein Institutes for Medical Research, Northwell Health; Abigail Dumes, University of Michigan; E. Wesley Ely, Vanderbilt University Medical Center; Dennis Larry Kolson, University of Pennsylvania; Jerry A. Krishnan, University of Illinois Chicago; Peter Palese, Icahn School of Medicine at Mount Sinai; Caitlin Pedati, Virginia Beach Department of Public Health; Mark Smolinski, Ending Pandemics; Linda Sprague Martinez, University of Connecticut School of Medicine, Health Disparities Institute, UConn Health; Andrea B. Troxel, New York University Grossman School of Medicine; Monica Verduzco-Gutierrez, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio.

NATIONAL ACADEMY OF MEDICINE FELLOWS Paule Joseph, National Institutes of Health; Ben Weston, Medical College of Wisconsin, Milwaukee County Office of Emergency Management.

STUDY STAFF Lisa Brown, Study Director; Tequam Worku, Program Officer; Shalini Singaravelu, Program Officer; Matthew Masiello, Associate Program Officer; Margaret McCarthy, Research Associate (until December 31, 2023); Burgess Manobah, Research Associate (from January 1, 2024); Rayane Silva-Curran, Senior Program Assistant; Clare Stroud, Senior Board Director, Board on Health Sciences Policy; CONSULTANT Ilana Goldowitz, Striga Scientific, LLC; INTERN Jacqueline Brenner, University of Miami Miller School of Medicine.

FOR MORE INFORMATION

This Consensus Study Report Highlights was prepared by the Board on Health Sciences Policy based on the Consensus Study Report A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences (2024).

The study was sponsored by the Administration for Strategic Preparedness and Response and the Office of the Assistant Secretary for Health. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.


To read the full report, visit nationalacademies.org/long-covid-definition.

Health and Medicine Division